• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.69% Nasdaq Down1.07%

    More On BIO.DE



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Biotest AG (BIO.DE)

    20.60 Up 0.68(3.39%) 11:35AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Biotest AG
    Landsteinerstrasse 5
    Dreieich, 63303
    Germany - Map
    Phone: 49 6103 801 4406
    Fax: 49 6103 801 347
    Website: http://www.biotest.de

    Index Membership:N/A
    Full Time Employees:2,218

    Business Summary 

    Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for the treatment of primary immune deficiency; Cytotect for cytomegalovirus (CMV) infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for the treatment of hepatitis B re-infection prophylaxis; Nabi-HB for post exposure prophylaxis; Intratect for primary immune and secondary antibody deficiency syndromes, as well as for autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; and Pentaglobin to treat bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat CMV infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for rheumatoid arthritis and psoriasis; Fibrinogen to treat fibrinogen deficiency; and IgM concentrate for the treatment of bacterial infections. It has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biotest AG

    Key Executives 
    Dr. Bernhard R. M. Ehmer M.D., 60
    Chairman of Management and Chief Exec. Officer
    Dr. Michael Ramroth ,
    Chief Financial Officer, Head of Fin.s & Central Services and Member of the Management Board
    Dr. Georg Floß ,
    Chief Operating Officer and Member of Board of Management
    Dr. Monika Buttkereit ,
    Head of Investor Relations
    Dr. Joachim Herborg ,
    Exec. VP of Marketing & Sales - Pharma
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.